Minzhen Xu
Geen lopende functies
Vermogen: 408 000 $ op 31-05-2024
Profiel
Minzhen Xu worked as a Vice President at NuGenerex Immuno-Oncology, Inc.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 27-09-2023 | 400 000 ( 5.95% ) | 408 000 $ | 31-05-2024 |
Eerdere bekende functies van Minzhen Xu
| Bedrijven | Functie | Einde |
|---|---|---|
| NUGENEREX IMMUNO-ONCOLOGY, INC. | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
NuGenerex Immuno-Oncology, Inc.
 NuGenerex Immuno-Oncology, Inc. BiotechnologyHealth Technology NuGenerex Immuno-Oncology, Inc. is an oncology company focuses on the modulation of the immune system to treat cancer. It develops immunotherapeutic products and vaccines based on proprietary, patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (MHC) class II associated invariant chain that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. The company was founded on October 8, 1993 and is headquartered in Miramar, FL. | Health Technology |
